This Article Full Text Full Text (PDF) CME: Take the course for this article: Managing Vesicant Extravasations eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Reprints/Permissions Google Scholar Articles by Schulmeister, L. PubMed Articles by Schulmeister, L.

The Community Oncologist

Managing Vesicant Extravasations

Oncology Nursing Consultant, River Ridge, Louisiana, USA

Key Words. Vesicant extravasation • Vesicant extravasation treatment • Tissue necrosis

Correspondence: Lisa Schulmeister, R.N., M.N., A.P.R.N.-B.C., O.C.N.®, F.A.A.N., 282 Orchard Road, River Ridge, Louisiana 70123, USA. Telephone: 504-739-9462; Fax: 504-738-2087; e-mail: LisaSchulmeister{at}hotmail.com

Disclosure: L.S. has acted as a consultant to TopoTarget USA (manufacturer of Totect^TM, which is mentioned in this article), and has received an honorarium from Baxter (manufacturer of Hylenex®, which is mentioned in this article) for participation in a focus group. No other potential conflicts of interest were reported by the author, planners, reviewers, or staff managers of this article.

Extravasation is an unusual but potentially severe complication of vesicant chemotherapy administration. Some extravasation injuries prompt litigation and the oncologist's actions, or lack of action, are scrutinized in the courtroom. This article presents advice and recommendations for treating patients who receive vesicants and includes a discussion of FDA-approved vesicant extravasation treatments and antidotes.